Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generation of Regulatory T Cells Against Islet Neoantigen.

European journal of immunology·2026
Same author

Review of Type 1 Diabetes-Reply.

JAMA·2026
Same author

Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro.

PloS one·2026
Same author

Low-Dose Antithymocyte Globulin in Type 1 Diabetes: Real-World Exploratory Observation of C-Peptide by Modified Quantitative Response (mQR).

Diabetes care·2026
Same author

The Importance of C-Peptide for Developing T1D Disease-Modifying Therapies.

Diabetes care·2026
Same author

Divergent CD27 expression marks the Treg induction trajectory.

Frontiers in immunology·2026
Same journal

Less Is More? Physical Inactivity and Increased Risk of Diabetes-Related Foot Ulceration-A Systematic Review.

Diabetes/metabolism research and reviews·2026
Same journal

Analysis of Circulating Long Non-Coding RNA in Prediabetes or Newly Diagnosed Type 2 Diabetes Subjects With or Without Heart Stress.

Diabetes/metabolism research and reviews·2026
Same journal

Biomarkers for Diabetic Peripheral Artery Disease: An Integrated Review and Clinical Perspective.

Diabetes/metabolism research and reviews·2026
Same journal

Retinol, Carotenoid, and Tocopherol Intake and Status, and the Risk of Islet Autoimmunity and Type 1 Diabetes: The Environmental Determinants of Diabetes in the Young Study.

Diabetes/metabolism research and reviews·2026
Same journal

Glucokinase Regulatory Protein Gene Polymorphism as a Predictive Biomarker for Early Renal Injury in Newly Diagnosed Early-Onset Type 2 Diabetes Mellitus.

Diabetes/metabolism research and reviews·2026
Same journal

Hearing Loss in Adults With Diabetes and Prediabetes: A Systematic Review and Meta-Analysis.

Diabetes/metabolism research and reviews·2026
See all related articles

Related Experiment Videos

Challenges in developing endpoints for type 1 diabetes intervention studies.

Simona Cernea1, Itamar Raz, Kevan C Herold

  • 1Department of Endocrinology and Diabetes, University Campus Bio-Medico, Rome, Italy.

Diabetes/Metabolism Research and Reviews
|September 23, 2009
PubMed
Summary
This summary is machine-generated.

Developing effective type 1 diabetes interventions requires standardized methods to measure beta-cell function. C-peptide tests and autoantibody biomarkers are key for assessing treatment efficacy and predicting outcomes.

Related Experiment Videos

Area of Science:

  • Endocrinology and Immunology
  • Diabetes Research
  • Clinical Trial Design

Background:

  • Challenges in type 1 diabetes (T1D) intervention development include non-standardized protocols and unclear efficacy endpoints.
  • Assessing beta-cell function for T1D interventions necessitates reliable assays and parameters.

Framework:

  • Measuring C-peptide levels post-mixed-meal stimulus under standardized conditions is an accepted method for evaluating endogenous insulin secretion.
  • Preventive T1D interventions require validated mechanistic or immunological markers correlating with clinical outcomes.

Implementation:

  • For early-stage preventive studies in T1D, developing two or more islet autoantibodies can serve as disease biomarkers.
  • Diabetes diagnostic criteria are considered suitable endpoints for evaluating intervention success in T1D.

Implications:

  • Standardized C-peptide measurement and validated biomarkers are crucial for advancing T1D intervention strategies.
  • Consensus on efficacy endpoints will accelerate the development of therapies to preserve or restore insulin production in T1D.